Muscle Invasive Bladder cancer- Pipeline Insight, 2024

Muscle Invasive Bladder cancer- Pipeline Insight, 2024

DelveInsight’s, “Muscle Invasive Bladder cancer- Pipeline Insight, 2024” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Muscle Invasive Bladder cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Muscle Invasive Bladder cancer: Understanding

Muscle Invasive Bladder cancer: Overview

Muscle invasive bladder cancer (MIBC) is a type of bladder cancer that has grown into the muscle layer of the bladder wall. This is a more aggressive form of bladder cancer compared to non-muscle invasive types and requires more intensive treatment. MIBC accounts for about 25% of all bladder cancer cases and is associated with a higher risk of metastasis and lower survival rates. The main risk factors include smoking, exposure to industrial chemicals, chronic bladder inflammation, and certain genetic predispositions.

The symptoms of MIBC are often similar to those of non-muscle invasive bladder cancer but tend to be more severe. Common signs include hematuria (blood in the urine), which is often painless and the most common initial symptom. Patients may also experience dysuria (painful urination), frequent urination, and urgency. Advanced symptoms might include pelvic pain, lower back pain, weight loss, and fatigue, indicating that the cancer may have spread beyond the bladder.

The primary causes of MIBC are similar to those of other bladder cancers. Tobacco smoke is the most significant risk factor, contributing to about half of all cases. Occupational exposure to certain chemicals, such as aromatic amines found in the dye industry, is also a known risk factor. The pathophysiology involves the accumulation of genetic mutations and epigenetic alterations that lead to the transformation of normal urothelial cells into cancerous cells. These mutations often affect key regulatory genes involved in cell cycle control, apoptosis, and DNA repair, leading to uncontrolled cell growth and invasion into the bladder muscle.

Diagnosis of MIBC typically involves a combination of clinical evaluation, imaging, and histopathological examination. Initially, a urine cytology test may be performed to detect cancer cells in the urine. Cystoscopy is a crucial diagnostic tool, allowing direct visualization of the bladder interior and biopsy of suspicious lesions. Imaging studies such as CT scans, MRI, and PET scans are used to determine the extent of tumor invasion and to check for metastasis. The definitive diagnosis is made based on biopsy results, where the presence of cancer cells in the bladder muscle layer confirms MIBC.

Treatment for MIBC usually involves a multi-modal approach, including surgery, chemotherapy, and sometimes radiation therapy. Radical cystectomy, the removal of the entire bladder and surrounding tissues, is the standard surgical treatment. In some cases, a partial cystectomy might be considered. Neoadjuvant chemotherapy, administered before surgery, is often recommended to shrink the tumor and improve surgical outcomes. For patients who cannot undergo surgery, a combination of chemotherapy and radiation therapy may be used. Immunotherapy, particularly with checkpoint inhibitors, has emerged as a promising treatment option for advanced or metastatic MIBC. The choice of treatment is tailored to the patient's overall health, cancer stage, and personal preferences.

""Muscle Invasive Bladder cancer- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Muscle Invasive Bladder cancer pipeline landscape is provided which includes the disease overview and Muscle Invasive Bladder cancer treatment guidelines. The assessment part of the report embraces, in depth Muscle Invasive Bladder cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Muscle Invasive Bladder cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Muscle Invasive Bladder cancer R&D. The therapies under development are focused on novel approaches to treat/improve Muscle Invasive Bladder cancer.

Muscle Invasive Bladder cancer Emerging Drugs Chapters

This segment of the Muscle Invasive Bladder cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Muscle Invasive Bladder cancer Emerging Drugs

• TAR-200 : Janssen Research & Development, LLC

TAR-200 is a novel investigational small molecule targeted releasing system enabling controlled release of gemcitabine into the bladder, sustaining local drug exposure for weeks at a time. The safety and efficacy of TAR-200 are being evaluated in Phase II and Phase III studies in patients with muscle-invasive bladder cancer in SunRISe-2 and SunRISe-4. Currently, the drug is in Phase III stage of its development for the treatment of Muscle Invasive Bladder Cancer.

• AU-011: Aura Biosciences

AU-011 is a first-in-class targeted therapy in development for the muscle Invasive Bladder Cancer and noninvasive muscle bladder cancer. The drug candidate is being developed by Aura Biosciences. The drug is death stimulants and photosensitisers and also works as reactive oxygen species stimulants thus having mechanism of action. Currently, the drug is in Phase I stage of its development for the treatment of Muscle Invasive Bladder Cancer.

Further product details are provided in the report……..

Muscle Invasive Bladder cancer: Therapeutic Assessment

This segment of the report provides insights about the different Muscle Invasive Bladder cancer drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Muscle Invasive Bladder cancer
• There are approx. 10+ key companies which are developing the therapies for Muscle Invasive Bladder cancer. The companies which have their Muscle Invasive Bladder cancer drug candidates in the most advanced stage, i.e. phase III include, Janssen Research & Development, LLC.
• Phases

DelveInsight’s report covers around 10+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Muscle Invasive Bladder cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical
• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Muscle Invasive Bladder cancer: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Muscle Invasive Bladder cancer therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Muscle Invasive Bladder cancer drugs.

Muscle Invasive Bladder cancer Report Insights

• Muscle Invasive Bladder cancer Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Muscle Invasive Bladder cancer Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Muscle Invasive Bladder cancer drugs?
• How many Muscle Invasive Bladder cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Muscle Invasive Bladder cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Muscle Invasive Bladder cancer therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Muscle Invasive Bladder cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Aura Biosciences
• Janssen Research & Development, LLC
• Asieris Pharmaceuticals.
• RemeGen Co., Ltd.

Key Products

• TAR-200
• AU-011
• APL-1202
• RC48-ADC